IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor. METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound. RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred. CONCLUSIONS: IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, IdeS is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients (123).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global burden of group A streptococcal diseases
Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70267-x · Cited by 2,998
Significance of the Positive Crossmatch Test in Kidney Transplantation
Patel, R., & Terasaki, P. I. (1969) · New England Journal of Medicine · doi:10.1056/nejm196904032801401 · Cited by 1,508
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350 · cited 1×
“Scoring of various values (complement factor 4d deposition [C4d+], interstitial fibrosis and tubular atrophy [IFTA], glomerulitis plus peritubular capillaritis [GPC], transplant glomerulopathy [TG], and thrombotic microangiopathy [TMA]) was based on Banff 2013 criteria.(18) T bars indicate 1 SD.”
MethodSelf-citationThe Quality of Life of Patients with End-Stage Renal Disease
Evans, R. W., Manninen, D. L., Garrison, L. P., Hart, L. G., Blagg, C. R., Gutman, R. A., Hull, A. R., & Lowrie, E. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120905 · Cited by 1,183
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., van Huyen, J.-P. D., Mooney, N., Suberbielle, C., Frémeaux-Bacchi, V., Méjean, A., Desgrandchamps, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302506 · Cited by 852
Comparison of Survival Probabilities for Dialysis Patients vs Cadaveric Renal Transplant Recipients
Port, F. K. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510110079036 · Cited by 825
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Lefaucheur, C., Loupy, A., Hill, G. S., Andrade, J., Nochy, D., Antoine, C., Gautreau, C., Charron, D., Glotz, D., & Suberbielle-Boissel, C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101065 · Cited by 789
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Self-citationDesensitization in HLA-Incompatible Kidney Recipients and Survival
Montgomery, R. A., Lonze, B. E., King, K. E., Kraus, E. S., Kucirka, L. M., Locke, J. E., Warren, D. S., Simpkins, C. E., Dagher, N. N., Singer, A. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012376 · Cited by 687
IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
von Pawel-Rammingen, U. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1607 · Cited by 473
Research works printed but not linked: 1
- 12. ies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398406.
Cited by
Items 201–300 of 376
Green, H., Nesher, E., Aizner, S., Israeli, M., Klein, T., Zakai, H., Rahamimov, R., Rozen‐Zvi, B., & Mor, E. (2019) · Clinical Transplantation · doi:10.1111/ctr.13562 · Cited by 7
Wang, L., Ma, X., Xia, H., Sun, X., Yu, L., Yang, Q., Hu, Z., Zhao, Y., Hu, W., & Jiang-hua, R. (2021) · BioMed Research International · doi:10.1155/2021/9933136 · Cited by 7
RetractedKahn, F., Shannon, O., & Björck, L. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15433 · Cited by 7
Altındal, M., Güldan, M., Özbek, L., Abdel‐Rahman, S. M., Unlu, S., Murt, A., Hasbal, N. B., Yıldız, A., Ferro, C. J., Covic, A. C., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf219 · Cited by 6
Molecular basis of Fab-dependent IgA antibody recognition by gut-bacterial metallopeptidases
Marquez-Monino, M. A., Gascueña, A. M., Azzam, T., Persson, A., Manzanares-Gomez, A., Aguillo-Urarte, M., Brown, T. T., Montero-Sagarminaga, A., Lood, R., Naegeli, A., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00518-w · Cited by 7
Innovative immunosuppression in kidney transplantation: A challenge for unmet needs
Salvadori, M., & Tsalouchos, A. (2022) · World Journal of Transplantation · doi:10.5500/wjt.v12.i3.27 · Cited by 8
Chandak, P., Phillips, B. L., Bennett, D., Uwechue, R., Kessaris, N., Shaw, O., Maggs, T., Woodford, L., Veniard, D., Perera, R., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104365 · Cited by 7
Chandramohan, D., Adisa, O., Patel, D., Ware, E. E., Eleti, N., & Agarwal, G. (2024) · Life · doi:10.3390/life14080998 · Cited by 10
Approach to Highly Sensitized Kidney Transplant Candidates and a Positive Crossmatch
Sethi, S., Ammerman, N., Vo, A. A., & Jordan, S. C. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.004 · Cited by 7
Self-citationEmerging strategies for antibody-mediated rejection
Malvezzi, P. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001016 · Cited by 7
Therapeutic issues in Guillain–Barré syndrome
Magy, L., & Frachet, S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2212163 · Cited by 6
Significance of biologics in renal transplantation
Grgic, I., & Chandraker, A. K. (2017) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000496 · Cited by 6
Doberer, K., Bond, G., Kläger, J. P., Regele, H. M., Straßl, R. P., Reindl‐Schwaighofer, R., Scheriau, G., Wahrmann, M., Kikić, Ž., Faé, I., et al. (2020) · Blood Purification · doi:10.1159/000506504 · Cited by 6
Chop-Chop: The Future of Bacterial Enzymes in Transfusion Medicine
Klontz, E. H. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.05.003 · Cited by 6
Mehra, M. R., Mohiuddin, M. M., Reichart, B., Abicht, J., Boulet, J., Cooper, D. K. C., Cowan, P. J., Crespo-Leiro, M. G., Denner, J., Fishman, J. A., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.12.012 · Cited by 5
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
“However, most of these approaches remain at the preclinical or early clinical stage and require further validation in controlled trials [166,170,173,213].”
Updated management for antibody-mediated rejection: opportunity to prolong kidney allograft survival
Townamchai, N., & Avihingsanon, Y. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000843 · Cited by 5
Isath, A. M., VUKIĆEVIĆ, M., MOAYEDIFAR, R., Zuckermann, A. O., & Mehra, M. R. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.016 · Cited by 6
The Promise of Complement Therapeutics in Solid Organ Transplantation
Steggerda, J. A., & Heeger, P. S. (2024) · Transplantation · doi:10.1097/tp.0000000000004927 · Cited by 6
“112,113 Jordan et al 113 performed a phase I/II open-label clinical trial with the administration of IdeS to highly sensitized recipients and showed universal response with reduction/elimination of DSAs to support HLA-incompatible transplantation of these recipients.”
Tatapudi, V., Lonze, B. E., Wu, M. T., & Montgomery, R. A. (2018) · Case Reports in Nephrology and Dialysis · doi:10.1159/000486158 · Cited by 5
Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy
Jordan, R. E., Fan, X., Salazar, G. T., Zhang, N., & An, Z. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1480300 · Cited by 5
“IdeS is unique in its selectivity for human IgGs and, in addition to its reagent uses, has potential therapeutic applications for counteracting autoimmunity.(19,21,27,28) IdeS hydrolyzes bonds in the lower hinge of all four human IgG subclasses – but not those of other mammalian groups.”
BackgroundTreatment of Pulmonary Vasculitis
Guillevin, L., & Terrier, B. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0038-1669414 · Cited by 5
Kielar, M., Gala‐Błądzińska, A., Dumnicka, P., Ceranowicz, P., Kapusta, M., Naumnik, B., Kubiak, G., Kuźniewski, M., & Kuśnierz‐Cabala, B. (2021) · Biomolecules · doi:10.3390/biom11060773 · Cited by 5
A New Treatment Option for Highly Sensitized Patients Awaiting Kidney Transplantation
Akalin, E. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.10.024 · Cited by 5
Long-term Challenges After Solid Organ Transplantation
Legendre, C. M., Viebahn, R., Fehrman‐Ekholm, I., Masnou, N., Berenguer, M., Potena, L., Wennberg, L. M., O’Grady, J., Epailly, É., Diekmann, F., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002316 · Cited by 5
Self-citationA Bacterial IgG-Degrading Enzyme to Unhinge Antibodies
Ingelfinger, J. R. (2017) · New England Journal of Medicine · doi:10.1056/nejme1707604 · Cited by 5
Segundo, D. S., Comins‐Boo, A., & López‐Hoyos, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020630 · Cited by 4
“The first results of the combined experience of two independent open-label trials with 25 HS patients who underwent kidney transplantation were published in 2017 [88].”
Taner, T., Biggins, S. W., Cummins, N. W., Daly, R. C., Dietz, A. B., Emamaullee, J. A., Gandhi, M. J., Heimbach, J. K., Patel, J. K., Pereira, N. L., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.01.012 · Cited by 4
New approach to desensitization in solid organ transplantation-imlifidase
Durlik, M. (2022) · Frontiers in Transplantation · doi:10.3389/frtra.2022.951360 · Cited by 4
Adjei, M. A., Wisel, S. A., Ammerman, N., Vo, A. A., Guindi, M. M., Kosari, K., Voidonikolas, G., Todo, T., Nissen, N. N., Jordan, S. C., et al. (2023) · Transplantation Reports · doi:10.1016/j.tpr.2023.100145 · Cited by 4
Self-citationMizera, J., Pilch, J., Giordano, U., Krajewska, M., & Banasik, M. (2023) · Life · doi:10.3390/life13071458 · Cited by 4
“Abbreviations The following abbreviations are used in this manuscript: ABMR Antibody-mediated rejection TCMR t-cell-mediated rejection IVIG intravenous immunoglobulin HLA human leukocyte antigen DSA donor-specific antibodies CA chronic active PLEX plasma exchange KDIGO Kidney Disease: Improving Global Outcomes IdeS im…”
BackgroundInfluentialMartinino, A., Smith, T. J., Elmore, Z. C., Yoon, J., Ladowski, J. M., Schiliró, D., Hull, J. A., Schwalb, A., Hu, M., Spangler, R. D., et al. (2025) · Xenotransplantation · doi:10.1111/xen.70023 · Cited by 5
RetractedNovel pretransplant desensitization strategies in heart transplantation
Coutance, G., Chong, A. S., & Habal, M. V. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100242 · Cited by 4
“52 The use of imlifidase has recently been reported in a lung transplant recipient with favorable short-term outcomes.”
IdeS to desensitize organ allograft recipients
Böhmig, G. A., & Rostaing, L. P. E. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.128 · Cited by 4
Desensitization in HLA Incompatible Transplantation
Park, B. G. (2019) · The Korean Journal of Blood Transfusion · doi:10.17945/kjbt.2019.30.1.1 · Cited by 4
“IgG 항체를 성공적으로 제거한 임상 연구 결과가 보고되어, 추가 임상 연구가 진행 중이다[43].”
Guo, Z., Zhao, D., Sa, R., Wang, L., Li, S., Zhao, G., Zhu, L., & Chen, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223567 · Cited by 4
“Follow-up (m), median (IQR) 51 (18, 68) 41 (22, 61) 0.”
BackgroundIdentification of bacterial protease domains that cleave human IgM
Windgassen, T. A., Kruse, N., Ferrer, B., Du, F., Kumar, H., & Silverman, A. P. (2023) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2023.110366 · Cited by 4
Zhang, Z., Wilson, N. A., Chinnadurai, R., Panzer, S. E., Redfield, R. R., Reese, S. R., Galipeau, J., & Djamali, A. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000827 · Cited by 6
IdeS in anti–glomerular basement membrane disease: Is this the new deal?
Rafat, C., & Luque, Y. (2019) · Kidney International · doi:10.1016/j.kint.2019.08.017 · Cited by 4
Tromp, A. T., Zhao, Y., Jongerius, I., Heezius, E., Abrial, P., Ruyken, M., van Strijp, J. A. G., de Haas, C. J. C., Spaan, A. N., van Kessel, K. P. M., et al. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045534 · Cited by 4
“However, during the combined phase I and II trials, a total of 38 serious adverse effects in 15 patients were witnessed (Jordan et al., 2017).”
BackgroundCompatibility, Kidney Paired Donation, and Incompatible Living Donor Transplants
Garg, N., Gill, J., & Mandelbrot, D. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-53618-3_10 · Cited by 4
Immunosuppression in the Age of Precision Medicine
Gabardi, S. (2022) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2022.01.001 · Cited by 4
Update on Desensitization Strategies and Drugs on Hyperimmune Patients for Kidney Transplantation
Salvadori, M. (2023) · Transplantology · doi:10.3390/transplantology4030014 · Cited by 4
“A study from Jordan et al. [72] represents the first pilot study that combines two phase 1–2 trials undertaken independently.”
La région charnière des anticorps thérapeutiques: L’importance capitale d’une courte séquence
Deveuve, Q., Gouilleux‐Gruart, V., Thibault, G., & Lajoie, L. (2019) · médecine/sciences · doi:10.1051/medsci/2019218 · Cited by 9
Xu, Z., Sun, X., Ma, X., Bo, T., Wu, J., He, Y., Zhao, Y., Mao, H., Yang, J., Jiang, D., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75052-6 · Cited by 3
Bertrand, D., Dard, C., Kaveri, R., Jouvé, T., Malvezzi, P., Rostaing, L. P. E., Guerrot, D., Lemoine, M., Laurent, C., Noble, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1661977 · Cited by 3
Reuter, S., Benning, L., Dick, A., Dilz, L.-M., Einecke, G., Emmerich, F., Grahammer, F., Großmann, R., Gwinner, W., Halleck, F., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1846251 · Cited by 3
“…Sweden) cleaves human IgG at the hinge region in two steps, thereby reducing the HLA antibody (HLAab) load below the detection limit within 60 – 240 min and converting a previously positive crossmatch (XM), which is a contraindication for kidney transplantation, into a negative result (15, 16).”
Treatment Strategies for Antibody-mediated Rejection in Kidney Transplantation and Its Prevention
Cocco, P. D., Fratti, A., Kaylan, K. B., Tzvetanov, I. G., & Benedetti, E. (2020) · OBM Transplantation · doi:10.21926/obm.transplant.2003119 · Cited by 3
Vantair, N., Leising, M., Najor, M. S., Juma, Y. S., Kwon, D. H., Kallakury, B., Gilbert, A. J., Verbesey, J. E., Rodrigo, M. E., Sheikh, F. H., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.03.022 · Cited by 3
Diagnosis, Treatment, and Outcomes of Antibody-Mediated Rejection in Kidney Transplantation
Tatapudi, V., & Lonze, B. E. (2018) · InTech eBooks · doi:10.5772/intechopen.75770 · Cited by 3
“Just as new agents are being developed to remove antibody [127], and interrupt the pathways that impart antibody-mediated injury, so too are innovative, increasingly specific, and less invasive procedures for the diagnosis of AMR.”
BackgroundImmunosuppression in sensitized recipients
Echterdiek, F., Latus, J., & Schwenger, V. (2019) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000721 · Cited by 3
“[29] recently reported about two phase 1–2 studies on the use of an IgG-degrading enzyme derived from Streptococcus pyogenes (IdeS), an endopeptidase that cleaves IgG into Fc and F(ab)2 fragments thus inhibiting CDC and antibody-dependent cellular cytotoxicity mediated by IgG.”
BackgroundImmunological Characteristics and Management of Kidney Transplantation
Kim, M.-G. (2020) · Korean Journal of Medicine · doi:10.3904/kjm.2020.95.1.18 · Cited by 3
Rußwurm, M., Maier-Giebing, T., Kortus-Goetze, B., Russ, P., Gröne, H., & Hoyer, J. D. (2023) · Blood Purification · doi:10.1159/000528748 · Cited by 3
Recombinant Endopeptidases IdeS and IdeZ and Their Potential Application
Бокша, И. С., Lunin, V. G., Danilova, T. A., Poponova, M. S., Polyakov, N. B., Lyashchuk, A. M., Konstantinova, S. V., Galushkina, Z. M., & Ustenko, E. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923060020 · Cited by 5
Prime Time for HLA Desensitization: Imlifidase in the Spotlight
Bestard, O., Moreso, F., & Dorling, A. (2023) · Transplant International · doi:10.3389/ti.2023.11616 · Cited by 3
“By transiently depleting all circulating IgG, including HLA antibodies for several days, Imlifidase can uniquely create a window of opportunity for highly sensitized patients with high pathogenic anti-HLA antibody levels to undergo kidney transplantation [5].”
BackgroundBharadwaj, P., & Ackerman, M. E. (2021) · Experientia supplementum · doi:10.1007/978-3-030-76912-3_18 · Cited by 3
Point-Counterpoint: Desensitization to improve the likelihood of lung transplantation
Roux, A., & Hachem, R. R. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.10.006 · Cited by 3
Beaudrey, T., Apithy, M.-J., Olagne, J., Lemonnier, L., Perrin, P., Gautier-Vargas, G., Jahn, I., Radosavljevic, M., Bahram, S., Carapito, R., et al. (2025) · Human Immunology · doi:10.1016/j.humimm.2024.111213 · Cited by 2
Desensitization With Imlifidase: Overcoming Immunological Barriers in Kidney Transplantation
Hernández-Velasco, P., Martínez, E. G., Fernandez, N. I. P., González, E., González-García, C., Sierra, E. M., & Belmonte, A. A. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101076 · Cited by 2
Martinino, A., Li, Z., Smith, T. J., Schiliró, D., Elmore, Z. C., Yoon, J., Fatzaun, E., Belloni, R., Ferrara, V. Z., Tunbridge, M. J., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.10.007 · Cited by 2
Heart Transplantation: Is It Still the Gold Standard?
Kakoudaki, T., Aurovind, S., Kydd, A., & Bhagra, S. K. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.1018 · Cited by 2
Sensitization and Deceased-Donor Kidney Transplant Access in France
Bertrand, D., Gatault, P., Poulain, C., Colosio, C., Danthu, C., Duveau, A., Écotière, L., Garrouste, C., Meur, Y. L., Morin, M.-P., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106340 · Cited by 2
“28 In France, consensus guidance from the French Society of Transplantation 29 proposes structured selection criteria (e.g., very high sensitization such as cPRA $ 98%, age # 65 years, > 3 years on the waitlist), donor requirements, and intensive post-transplant monitoring, offering a standardized…”
Cao, J. D., Gao-Desliens, J., Valent, A., Knuchel-Legendre, N., Colpin, C., Guyon, H., Winstedt, L., Leborgne, C., Perret, G., Ronzitti, G., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.018 · Cited by 2
Self-citationReuter, S., Lachmann, N., de Ferrante, H. C., Böhmig, G. A., & Budde, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1868642 · Cited by 2
“Conversely, candidates who remain poorly transplantable despite these options represent the population in whom conventional desensitization, risk-adapted delisting, imli fi dase, or future immune-cell-targeting strategies become clinically justi fi able (2, 10).”
InfluentialSchmitz, R., Manook, M., Fitch, Z. W., Anwar, I. J., DeLaura, I. F., Olaso, D., Choi, A. Y., Yoon, J., Bae, Y., Song, M., et al. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1230393 · Cited by 2
“…survival (BAFF) (19), plasma cells (proteasome inhibitor, anti-CD38mAb) (17, 18, 20 – 22), antibodies (i.e., Imli fi dase or anti-FcRn mAb) (23 – 25) and complement activation or split products (i.e., Eculizumab, C1-INH) (26 – 28), and have been tested in the clinic or in pre-clinical models…”
BackgroundNavigating the nanoscale: Principles of body navigation
Abbasi, S., Dirisala, A., Carter, D. A. G., Paraiso, W. K. D., Li, J., & Tockary, T. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-823994-0.00002-5 · Cited by 2
Nakazawa, D. (2024) · Transplantation Reviews · doi:10.1016/j.trre.2024.100887 · Cited by 2
Complication from Desensitization
Han, D. J. (2019) · Springer eBooks · doi:10.1007/978-981-10-7046-4_6 · Cited by 4
Machacek, M. E., Fields, P. E., & Slawson, C. M. (2020) · Analytical Biochemistry · doi:10.1016/j.ab.2020.114001 · Cited by 2
“As evidence of the high specificity of the IgG endopeptidases, a homologous IgG endopeptidase, IdeS, has been successfully transfused into human patients to cleave antibodies generated against transplanted organs [12].”
BackgroundDaga, S., & Briggs, D. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101775 · Cited by 2
Recombinant endopeptidases IdeS and IdeZ and their potential applications
Бокша, И. С., Lunin, V. G., Danilova, T. A., Poponova, M. S., Polyakov, N. B., Lyashchuk, A. M., Konstantinova, S. V., Galushkina, Z. M., & Ustenko, E. V. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523060027 · Cited by 2
Imlifidase: Is it the Magic Wand in Renal Transplantation?
Krishnan, N. S., & Briggs, D. (2024) · Indian Journal of Nephrology · doi:10.25259/ijn_325_23 · Cited by 2
“20 published in 2017 the output from two independent phases 1–2 studies involving 25 patients, 11 patients in Sweden and 14 in the US, who had an HLA incompatible transplants following Imlifidase injection: 22 had DSAs, 18 of whom had a positive flow cytometry cross-match, and two were CDC…”
BackgroundBeing Thoughtful about Desensitization
Formica, R. N., & Kulkarni, S. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09000817 · Cited by 2
Post-transplant Management in Heart Transplant Recipients: New Drugs and Prophylactic Strategies
Fida, N., Tantrachoti, P., Guha, A., & Bhimaraj, A. (2021) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-021-00933-2 · Cited by 2
Efficient use of immunosuppressants for kidney transplants
Heo, E. J., Hong, S., & Chun, Y. (2022) · Journal of Health Economics · doi:10.1016/j.jhealeco.2022.102650 · Cited by 2
Immunological Assessment and Monitoring in Kidney Transplantation
Louis, K., Lefaucheur, C., & Loupy, A. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00282022 · Cited by 2
T-B Collaboration in Autoimmunity, Infection, and Transplantation
Ditoro, D. F., Murakami, N., & Pillai, S. S. (2024) · Transplantation · doi:10.1097/tp.0000000000004671 · Cited by 2
Antibody Mediated Rejection in Kidney Transplant Recipients
Kojc, N., & Haler, Ž. V. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85886 · Cited by 2
Evaluating Readministration of Adeno-Associated Virus for Gene Therapy
Arjomandnejad, M., & Keeler, A. M. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29204.mar · Cited by 2
Strategies for Access to Kidney Transplantation for Highly Sensitized and Incompatible Patients
Salvadori, M. (2023) · Transplantology · doi:10.3390/transplantology4020009 · Cited by 2
“Techniques to remove antibodies include plasmapheresis or immunoadsorption or IgG endopeptidase [13].”
Carpenter, M. C., Souter, S. C., Zipkin, R. J., & Ackerman, M. E. (2023) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2023.150779 · Cited by 1
AlNajjar, M., Rochat, R. H., Grimes, A. B., Navaei, A., Eagar, T. N., Martinez, C. A., Yassine, K., Krance, R. A., & Bhar, S. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31412 · Cited by 1
COOPER, D. L., Verceles, J. A., Kheradmand, T., Paroder, M., Lombardo, A., de Castro, A., Browne, R., Konopleva, M., Moavero, B., Goldfinger, M., et al. (2025) · Transfusion · doi:10.1111/trf.18374 · Cited by 1
Use of HLA desensitization in the management of renal transplant recipients in Europe
Rostaing, L. P. E., Böhmig, G. A., Taqi, M. M., & Gibbons, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1451135 · Cited by 1
“Although production of anti-HLA antibodies rebounds after duration of action, use of IVIG and rituximab following transplantation dampens this effect (27, 28).”
Lázár‐Molnár, E., Truax, C. M., Eiting, M. M., Jain, D., Hurst, D., Zukauckas, K., Pearce, A., Bergam, S., Gardner, S., Clayton, F. C., et al. (2025) · Human Immunology · doi:10.1016/j.humimm.2025.111584 · Cited by 1
Devriese, M., Carelli, I., Giraldo, L., Pin, A., Groshaeny, N., Silva, S. D., Bockermann, R., & Taupin, J. (2025) · HLA · doi:10.1111/tan.70502 · Cited by 1
Post‐Transplant DSA Monitoring After HLAi Kidney Transplantation: Key Time Points
Hijazi, G., Daga, S., Phillpott, M., Briggs, D., Krishnan, N. D., Higgins, R. M., & Khovanova, N. A. (2026) · HLA · doi:10.1111/tan.70537 · Cited by 1
Trends in nephrology: from nihilism to targeted treatment of antibody-mediated rejection
Pickl, J. F., & Oberbauer, R. W. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag011 · Cited by 1
Hannachi, E., Trecco, A., Daventure, V., Delignat, S., Bonilla, P., Lecerf, M., Thaunat, O., Dimitrov, J. D., Deligne, C., & Lacroix‐Desmazes, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1728855 · Cited by 1
“The therapeutic potential of IdeS (marketed as Ide fi rix ® ) has since been demonstrated in kidney transplant patients with donor speci fi c antibodies (11) and in patients with Goodpasture syndrome (12, 13).”
Pessatti, T. B., Schmuck, B., Karlsson, E., Greco, G., Pozzati, G., Stadlmayr, S., Lu, L., & Rising, A. (2026) · Communications Materials · doi:10.1038/s43246-026-01144-7 · Cited by 1
Safa, K., Pattanayak, V., Yee, A. J., & Chen, Y. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.07.019 · Cited by 1
Immunological considerations—HLA matching and management of high immunological risk recipients
Timofeeva, O. A., & Brown, J. (2021) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-021-01201-5 · Cited by 1
Transplanting highly sensitized patients
Habli, M., Belal, D., Sharma, A., & Halawa, A. M. (2023) · Journal of The Egyptian Society of Nephrology and Transplantation · doi:10.4103/jesnt.jesnt_34_22 · Cited by 1
Carpenter, M. C., Shrestha, S., Bharadwaj, P., Catalano, C., Sharma, S., Weiner, J. A., de Haan, N., Pongrácz, T., Moine, A. L., Holovská, V., et al. (2025) · Human Immunology · doi:10.1016/j.humimm.2025.111247 · Cited by 1
COOPER, D. L., Verceles, J. A., Kheradmand, T., Paroder, M., Lombardo, A., Goldfinger, M., Shah, N. N., Kornblum, N. S., Shapiro, L. C., Konopleva, M., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20004 · Cited by 1
Vermeidung und Behandlung von T‑Zell- und antikörpervermittelter Abstoßung
Reinold, J., Rohn, H., Witzke, O., & Feldkamp, T. (2018) · Der Nephrologe · doi:10.1007/s11560-018-0246-2 · Cited by 1
Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins
Chambers, E. T., & Kirk, A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00019-x · Cited by 1
Ramachandran, R., Bharati, J., Kenwar, D. B., Singh, S., Nada, R., Kohli, H. S., Rathi, M., Sharma, A., & Minz, R. (2020) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_45_19 · Cited by 1
Imlifidase Shows Promise for the Most Disadvantaged Sensitized Transplant Candidates
Schinstock, C. A. (2020) · Transplantation · doi:10.1097/tp.0000000000003497 · Cited by 1
The top‐trading cycles and chains solution for kidney exchange with immunosuppressants
Heo, E. J., Hong, S., & Chun, Y. (2021) · International Journal of Economic Theory · doi:10.1111/ijet.12298 · Cited by 1
Metadata
- Authors
- Jordan, S. C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., Zhang, X., Eich, T., Toyoda, M., Eriksson, B.-M., Ge, S., Peng, A., Järnum, S., Wood, K. J., Lundgren, T., Wennberg, L., Bäckman, L., Larsson, E., Villicana, R., Kahwaji, J., Louie, S., Kang, A., Haas, M., Nast, C., Vo, A., & Tufveson, G.
- Affiliations
- Uppsala University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-03
- Volume
- 377
- Issue
- 5
- Pages
- 442-453
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2740266422
- Cited by
- 377
- References
- 30
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 37 · 2023: 50 · 2022: 45 · 2021: 39 · 2020: 38 · 2019: 45 · 2018: 36 · 2017: 11
- FWCI
- 30.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- ide, HLA sensitization, kidney transplantation, desensitization, donor-specific antibodies, antibody-mediated rejection, cold ischemia time, delayed graft function, adverse events, antibody rebound
- MeSH terms
- Adult, Antibodies, Bacterial Proteins, Cysteine Endopeptidases, Female, Histocompatibility Testing, HLA Antigens, Humans, Immunoglobulin G, Immunosuppression Therapy, Male, Middle Aged, Transplantation Immunology, Complement C1q, Kidney Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.